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Type 1 and 2 diabetes result from the inability of pancreatic β-cells to secrete insulin necessary to maintain normal glucose homeostasis due to an acquired secretory defect and/or inadequate β-cell mass ([@r1],[@r2]). Studies by Dor et al. ([@r3]) and Teta et al. ([@r4]) emphasized the importance of the proliferative capacity of existing adult mouse β-cells to significantly contribute to the maintenance of β-cell mass during adulthood.

Mammalian target of rapamycin (mTOR) integrates signals derived from growth factors and nutrients to regulate protein translation, DNA synthesis, cell size, and proliferation ([@r5]--[@r10]). Target of rapamycin complex 1 (TORC1) is a functional association of mTOR with the scaffolding protein, raptor, whereas TORC2 is the functional association of mTOR with the protein, rictor. Rapamycin is able to disrupt raptor-mTOR interaction, whereas the rictor-mTOR complex is resistant to short-term exposure to rapamycin ([@r6]). Two prominent downstream targets of mTOR are 70-kDa ribosomal protein S6 kinase (S6K1) and eukaryotic initiation factor 4E--binding protein 1 (4EBP1). The overactivation of mTOR/S6K1 due to excess nutrients exerts a feedback inhibition through the upstream insulin receptor substrates 1 and 2 of insulin signaling that leads to decreased phosphorylation and activity of Akt ([@r1],[@r11]).

Glycogen synthase kinase-3 (GSK-3) derives its name from its ability to phosphorylate glycogen synthase and to suppress glycogen synthesis in skeletal muscle, but since this initial observation, a myriad of other GSK-3 targets have been identified ([@r12]--[@r14]). Two isoforms of GSK-3, α and β, exist and have overlapping functions. Lithium, an agent used as a mood stabilizer for decades, was first connected to GSK-3 inhibition for its ability to mimic Wnt signaling in *Xenopus* development ([@r15],[@r16]). Lithium also inhibits inositol monophosphatase and other related phosphomonoesterases ([@r17]). Recently, more specific and potent small molecule GSK-3 inhibitors have been developed, of which 1-azakenpaullone (1-Akp) is among the most potent and selective ([@r18],[@r19]).

Our previous studies demonstrated that glucose, leucine, cAMP, and modulation of ATP-sensitive K^+^ (K~ATP~) channels stimulate mTOR-dependent DNA synthesis and cell cycle progression in rat islets in a rapamycin-sensitive manner ([@r20]--[@r23]). In contrast to rat islets, human islets exhibited a variable response to these same stimuli, based on mTOR/S6K1 phosphorylation, and rarely increased DNA synthesis or entered the cell cycle. Because our previous studies on nutrient regulation of mTOR in rat islets identified a substantial dependence on mitochondrial metabolism, we extended our studies to nutrient metabolites. In preliminary experiments with the palmitate metabolite acetoacetate, we determined that the lithium component in commercially available acetoacetate salt significantly enhanced DNA synthesis and cell cycle progression in rodent and human islets in a rapamycin-sensitive manner. These effects of lithium were consistent with earlier findings by Sjoholm et al. ([@r24]), demonstrating that lithium triggered DNA synthesis in fetal rat islets, although the mechanism responsible for this effect was not identified. Here, we show that LiCl and the highly potent and specific GSK-3 inhibitor, 1-Akp, in combination with glucose, possess the ability to stimulate mTOR-dependent DNA synthesis, cell cycle progression, and proliferation of β-cells in human islets.

RESEARCH DESIGN AND METHODS
===========================

Lithium chloride (LiCl) was from Sigma, rapamycin was from Biomol, and 1-Akp was from Calbiochem.

Human islets.
-------------

Human islets were obtained from National Institutes of Health (NIH)-sponsored Islet Cell Resource (ICR) Basic Science Islet Distribution Program Centers (see [acknowledgments]{.smallcaps} for Centers) and the Juvenile Diabetes Research Foundation (JDRF) Human Islet Distribution Program at Washington University. All studies involving the use of isolated, cadaver-derived human islets were approved by the Washington University Human Studies Committee. Human islet donor data are as follows: 27 donors; 10 ICR Centers; 17 men, 10 women; age, mean 43.9 years (range 17--66); BMI, mean 29.3 (range 16.7--44.9); cold ischemia time, mean 9 h 6 min (range 1 h 25 min to 18 h 29 min); purity, mean 72.9% (range 20--95%); and viability, mean 90.3% (range 65--100%). Islets were handpicked for experiments.

Rat islet isolation.
--------------------

Rat islets were obtained from adult male Sprague-Dawley rats (∼250 g; Harlan Sprague-Dawley) as previously described ([@r20]). Studies were approved by the Washington University Animal Studies Committee.

\[^3^H\]thymidine incorporation.
--------------------------------

Islets (100) were cultured in Petri dishes for 4 days in 1 ml Connaught Medical Research Laboratories (CMRL) 1066 media \[8 mmol/l glucose, 10% fetal bovine serum (FBS), 2 mmol/l [l]{.smallcaps}-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin\] with treatment conditions as indicated in the figure legends at 37°C. During the final 24 h of the 96-h incubation, 10 μCi \[^3^H\]thymidine (Perkin-Elmer) was added, and \[^3^H\]thymidine incorporation was determined by trichloroacetic acid extraction and scintillation counting.

Flow cytometry.
---------------

Islets (200) were cultured for 4 days in 1 ml CMRL as described in the figure legends. Islets were dispersed with Dispase (Roche) in Ca^2+^- and Mg^2+^-free Hanks solution at 31°C. Cells were rinsed with PBS plus 1% FBS and resuspended in PBS plus 1% FBS containing 250 μg/ml RNase A and 10 μg/ml propidium iodide. The DNA content was analyzed using a FACSCalibur instrument, and data were analyzed with CellQuest software ([@r20]).

Immunohistochemistry.
---------------------

For Ki-67 expression, BrdU incorporation, and β-catenin nuclear translocation, human or rat islets (50--100) were treated for 4 days (1 day for β-catenin) and then dispersed using Accutase (Innovative Cell Technologies), and single-cell suspensions were cytospun onto coated slides (3,000--4,000 cells/slide). Cells were fixed in 4% paraformaldehyde, permeabilized using 1% Triton X-100 for 30 min, and blocked with 3% BSA for 1 h at room temperature. Indirect immunofluorescence was performed using primary antibodies, rabbit anti-insulin (1:100; Cell Signaling), mouse anti--Ki-67 (1:100; Dako), mouse anti--β-catenin (1:2,000; BD Biosciences), and secondary antibodies, Alexa 488 goat anti-rabbit (1:1,000) and Alexa 555 goat anti-mouse (1:1,000) (Molecular Probes). Nuclei were counterstained with 4′,6-diamindino-2-phenylindole (DAPI; Molecular Probes). Images were acquired using an Olympus BX61W1 microscope equipped with Olympus DP 70 cooled digital color camera.

Paraffin-embedded human islet sections (20--30 islets/section) were deparaffinized using xylene and rehydrated with graded alcohol. Antigen retrieval was carried out by microwaving the sections in 1 mmol/l EDTA, pH 8.0, for 15 min at high power followed by blocking in 3% BSA for 1 h at room temperature. The primary and secondary antibodies used were the same as above. For BrdU immunostaining, 1 μl cell proliferation labeling reagent (Amersham) was added to the treatment medium during the last 24 h of the 4-day incubation period and processed according to the manufacturer\'s protocol. Zeiss confocal microscope LSM 510 was used for Z-Stack analysis to confirm colocalization of Ki-67 or BrdU with insulin in human islets.

Proliferating β-cells were reported as the fold increase in Ki-67^+^ or BrdU^+^ insulin^+^/insulin^+^ cells compared with 5 mmol/l glucose. Nuclear translocation of β-catenin in β-cells is reported as fold increase in colocalized nuclear β-catenin^+^ insulin^+^/insulin^+^ cells.

Insulin secretion and content.
------------------------------

Islets were cultured for 4 days in CMRL medium containing 10% FBS, 8 mmol/l glucose ± 5 mmol/l LiCl or 5 μmol/l 1-Akp at 37°C. Static insulin secretion and islet insulin content were assayed as described in the figure legend.

Western blotting.
-----------------

Islets (100) were incubated in CMRL medium with 0.1% BSA (1 ml) and treated as indicated in the figure legends for 30 min. Islet proteins were resolved by SDS-PAGE, transferred to nitrocellulose, and immunoblotted using ECL (Amersham) for detection of total and phosphorylated forms of GSK-3α and -3β (Ser 21/9), total β-catenin, and phosphorylated S6 and Akt (Ser473) (Cell Signaling).

Expression of data and statistics.
----------------------------------

Data are presented as means ± SE. Statistically significant differences were assessed with unpaired *t* tests or one-way ANOVA followed by Newman-Keuls multiple comparison test. Significant differences are indicated by \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001.

RESULTS
=======

Effects of LiCl and 1-Akp on mTOR-mediated DNA synthesis.
---------------------------------------------------------

[Fig. 1*A*](#f1){ref-type="fig"} shows that LiCl at 5 and 10 mmol/l significantly enhanced DNA synthesis in human islets above that of 8 mmol/l glucose, whereas 15 mmol/l LiCl did not. Rapamycin (25 nmol/l) significantly inhibited DNA synthesis at all concentrations of LiCl (0, 5, 10, and 15 mmol/l) in the presence of 8 mmol/l glucose. Rapamycin at 100 nmol/l failed to inhibit DNA synthesis below that at 25 nmol/l rapamycin. As shown in [Fig. 1*B*](#f1){ref-type="fig"}, 1-Akp at 5, 10, and 15 μmol/l significantly enhanced DNA synthesis in human islets above that of 8 mmol/l glucose alone. Although 25 nmol/l rapamycin significantly inhibited DNA synthesis at 5, 10, and 15 μmol/l 1-Akp, the total amount of \[^3^H\]thymidine incorporation continued to rise with increasing doses of 1-Akp. Rapamycin at 100 nmol/l failed to significantly inhibit DNA synthesis below that of 25 nmol/l rapamycin.

[Figure 1*C*](#f1){ref-type="fig"} shows that LiCl at 5, 10, and 15 mmol/l significantly enhanced DNA synthesis above that of 8 mmol/l glucose in rat islets and was highly sensitive to inhibition by rapamycin. Although 1-Akp ([Fig. 1*D*](#f1){ref-type="fig"}) significantly increased DNA synthesis in rat islets above 8 mmol/l glucose alone, it did not continue to rise with increasing concentrations of 1-Akp in contrast to human islets ([Fig. 1*B*](#f1){ref-type="fig"}). Rapamycin (25 nmol/l) significantly inhibited DNA synthesis at 0, 5, 10, and 15 μmol/l 1-Akp.

Effects of exogenous insulin on DNA synthesis.
----------------------------------------------

[Figure 2*A*](#f2){ref-type="fig"} (filled columns) indicates that exogenous insulin (2, 20, or 200 nmol/l) failed to significantly increase DNA synthesis in human islets above that of basal glucose (5 mmol/l). 1-Akp ([Fig. 2*A*](#f2){ref-type="fig"}, open columns) at 10 and 15 μmol/l shows a marked increase in DNA synthesis. These studies suggest that stimulatory actions of 1-Akp on DNA synthesis are independent of endogenous insulin through the insulin signaling pathway. Rapamycin (25 nmol/l) significantly reduced DNA synthesis induced by 5 mmol/l glucose plus 200 nmol/l insulin, even below the levels at 5 mmol/l glucose. 1-Akp--dependent DNA synthesis in human islets was modestly, but not significantly, sensitive to rapamycin.

In contrast to human islets, rat islets ([Fig. 2*B*](#f2){ref-type="fig"}) show significantly enhanced DNA synthesis at 200 nmol/l insulin. As in human islets ([Fig. 2*A*](#f2){ref-type="fig"}), 25 nmol/l rapamycin significantly reduced DNA synthesis induced by 5 mmol/l glucose plus 200 nmol/l insulin. Rapamycin (25 nmol/l) reduced, whereas 100 nmol/l rapamycin completely inhibited, 15 μmol/l 1-Akp--mediated enhancement of DNA synthesis. Rat islets also incorporated significantly more \[^3^H\]thymidine overall than human islets.

GSK-3 inhibition and cell cycle progression.
--------------------------------------------

In [Fig. 3*A*](#f3){ref-type="fig"}, exposure of human islets to 10 mmol/l LiCl plus 5 mmol/l glucose, conditions that enhance basal DNA synthesis (data not shown), resulted in a significant decrease of cells in G~0~/G~1~ phase (76 ± 1.4 to 55 ± 4.0%), an increase of cells in S phase (5.4 ± 0.9 to 24 ± 5.0%), and a retention of cells in G~2~/M (12%) compared with 5 mmol/l glucose. Rapamycin (100 nmol/l) prevented the progression of cells from G~0~/G~1~ to S phase.

As shown in [Fig. 3*B*](#f3){ref-type="fig"}, human islets exposed to 15 μmol/l 1-Akp mimicked the stimulatory effects of LiCl on cell cycle progression ([Fig. 3*A*](#f3){ref-type="fig"}) in a rapamycin-sensitive manner. There was no detection of increased apoptosis under these conditions as shown in [Fig. 3*B*](#f3){ref-type="fig"}.

In [Fig. 3*C*](#f3){ref-type="fig"}, an increase in glucose from 5 to 8 mmol/l failed to exert any significant effects on G~0~/G~1~, S, or G~2~/M phases in human islets. In contrast, exposure of human islets to 8 mmol/l glucose plus 15 μmol/l 1-Akp significantly decreased cells in G~0~/G~1~ and increased cells in S phase with no change in G~2~/M. All of these changes were blocked by rapamycin.

In [Fig. 3*D*](#f3){ref-type="fig"}, exposure of rat islets to 10 mmol/l LiCl at 5 mmol/l glucose resulted in a significant decrease of cells in G~0~/G~1~ phase, an increase of cells in S phase, and a retention of cells in G~2~/M. Exposure of rat islets to an increase of glucose from 5 to 8 mmol/l alone produced a greater change from G~0~/G~1~ to S phase than LiCl at 5 mmol/l glucose. This effect of 8 mmol/l glucose on cell cycle progression was further increased by LiCl. This demonstrates the striking effect of glucose on cell cycle progression in rat islets in contrast to human islets ([Fig. 3*C*](#f3){ref-type="fig"}). In [Fig. 3*E*](#f3){ref-type="fig"}, exposure of rat islets to 8 mmol/l glucose compared with 5 mmol/l glucose resulted in a significant decrease of cells in G~o~/G~1~ phase and an increase of cells in S phase that was further increased by 1-Akp in a rapamycin-sensitive manner.

Effects of lithium and 1-Akp on insulin secretion and content.
--------------------------------------------------------------

[Figure 4*A*](#f4){ref-type="fig"} shows that after 4 days, human islets in all three treatment groups fail to significantly increase insulin secretion in response to 16.5 mmol/l glucose. The addition of forskolin, to increase cAMP concentrations, in combination with 16.5 mmol/l glucose significantly increased insulin secretion in control and 1-Akp--treated islets but not with LiCl treatment. Total islet insulin content on day 4 ([Fig. 4*B*](#f4){ref-type="fig"}) was significantly reduced compared with time 0 in all three treatment conditions, however, there were no differences between the treatment groups on day 4. In contrast, rat islets ([Fig. 4*C*](#f4){ref-type="fig"}) secrete insulin in response to glucose in all three treatment conditions, and no significant difference in insulin content between treatment groups or reduction from time 0 to day 4 was seen ([Fig. 4*D*](#f4){ref-type="fig"}).

Effects of glucose and GSK-3 inhibitors on β-cell proliferation in human islets.
--------------------------------------------------------------------------------

[Figure 5*B*](#f5){ref-type="fig"} demonstrates that human islets treated with 5 mmol/l LiCl or 5 μmol/l 1-Akp in the presence of 5 or 8 mmol/l glucose alone did not significantly increase the number of Ki-67^+^/insulin^+^ cells compared with 5 mmol/l glucose alone. However, combinations of 8 mmol/l glucose with either LiCl or 1-Akp show significant increases in Ki-67^+^/insulin^+^ cells compared with basal glucose. Glucose (8 mmol/l) plus LiCl significantly increased the number of Ki-67^+^/insulin^+^ cells compared with that of 8 mmol/l glucose alone or 5 mmol/l glucose plus LiCl. A fourfold increase in proliferating β-cells was noted in human islets treated with 8 mmol/l glucose plus LiCl (0.71 ± 0.3%) in contrast to 5 mmol/l glucose plus LiCl (0.168 ± 0.08%). Rapamycin treatment resulted in significantly fewer Ki-67^+^/insulin^+^ cells in all treatment conditions. [Figure 5*D*](#f5){ref-type="fig"} shows that glucose and GSK-3 inhibitors have a similar effect on BrdU labeling in β-cells as observed with Ki-67. Glucose (8 mmol/l) plus LiCl or 1-Akp also significantly increased the number of BrdU^+^/insulin^+^ cells compared with that of 8 mmol/l glucose alone or 5 mmol/l glucose plus LiCl or 1-Akp. [Figure 5*A*](#f5){ref-type="fig"} (*left*) is a representative confocal image of two paraffin-embedded intact human islets showing colocalization of Ki-67^+^ (red nuclei) and insulin^+^ (green cytoplasm) cells. [Figure 5*A*](#f5){ref-type="fig"}, *right panel* (*inset* from *left panel*) is a Z-Stack image magnified to confirm colocalization of Ki-67 and insulin in two adjacent β-cells or a dividing β-cell. [Figure 5*C*](#f5){ref-type="fig"} is a representative image of dispersed human β-cells stained for insulin and BrdU.

GSK-3 and mTOR signaling in human islets.
-----------------------------------------

[Figure 6*A*](#f6){ref-type="fig"} demonstrates that 10 mmol/l LiCl stimulates the phosphorylation of GSK-3β at both 5 and 8 mmol/l glucose in human islets. As shown in [Fig. 6*B*](#f6){ref-type="fig"}, LiCl increases accumulation of β-catenin, a downstream target of GSK-3, at 5 mmol/l glucose that is consistent with GSK-3 inhibition. An increase in glucose from 5 to 8 mmol/l also increases β-catenin accumulation. LiCl fails to further enhance β-catenin accumulation above 8 mmol/l glucose. Although the stimulatory effect of LiCl on GSK-3β phosphorylation at basal glucose is rapamycin insensitive, the stimulatory effects of intermediate glucose in enhancing β-catenin accumulation revealed a small degree of rapamycin sensitivity. In [Fig. 6*C*](#f6){ref-type="fig"}, an increase in glucose from 5 to 8 mmol/l failed to exert any significant effects on S6 phosphorylation, an indicator of mTOR activation, and 10 mmol/l LiCl was also ineffective. However, S6 phosphorylation was rapamycin sensitive.

In [Fig. 6*D*](#f6){ref-type="fig"}, 10 μmol/l 1-Akp stimulated β-catenin accumulation at basal glucose in a rapamycin-insensitive manner. Glucose (8 mmol/l) also enhanced β-catenin accumulation above 5 mmol/l glucose, and 1-Akp did not further potentiate this increase. Enhanced accumulation of β-catenin by 8 mmol/l glucose and 1-Akp was rapamycin sensitive. In [Fig. 6*E*](#f6){ref-type="fig"}, 1-Akp at 5 or 8 mmol/l glucose failed to increase S6 phosphorylation, and this basal level of S6 phosphorylation was rapamycin sensitive.

We next evaluated the effects of exogenous insulin on Akt and GSK-3β. As shown in [Fig. 6*F*](#f6){ref-type="fig"}, increasing insulin from 2 to 200 nmol/l at 5 mmol/l glucose was ineffective in stimulating Akt phosphorylation. However, coincubation of human islets with 200 nmol/l insulin plus rapamycin resulted in a significant phosphorylation of Akt, indicating the presence of a negative feedback inhibition of IRS signaling. This enhanced phosphorylation of Akt is consistent with an increase in the phosphorylation of GSK-3, a downstream target of Akt as shown in [Fig. 6*G*](#f6){ref-type="fig"}.

GSK-3 inhibition and β-catenin nuclear translocation.
-----------------------------------------------------

Because glucose or the GSK-3 inhibitors, LiCl and 1-Akp, increased steady-state levels of β-catenin in human islet cells, we assessed the degree of β-catenin translocation to the nucleus. [Figure 7*A* and *B*](#f7){ref-type="fig"} indicate that 10 mmol/l LiCl and 10 μmol/l 1-Akp significantly increased nuclear translocation of β-catenin in human β-cells compared with 5 or 8 mmol/l glucose. Although increasing glucose from 5 to 8 mmol/l increased β-catenin accumulation ([Fig. 6*B* and *D*](#f6){ref-type="fig"}), this did not result in the translocation of β-catenin to the nucleus. Unexpectedly, 25 nmol/l rapamycin strikingly blocked the increase in β-catenin translocation to the nucleus of human islet β-cells in the presence of lithium or 1-Akp. Human β-cells (green cytoplasm) were identified as positive for β-catenin nuclear translocation if nuclei were purple (combination of DAPI blue and β-catenin red). This staining pattern for nuclear β-catenin was also reported by Yi et al. ([@r25]).

DISCUSSION
==========

The focus of this study was to identify signaling pathways and potential therapeutic agents that would allow reproducible stimulation of DNA synthesis, cell cycle progression, and proliferation in human β-cells. We found that glucose, mTOR activity, and inhibition of GSK-3 together stimulated these regenerative processes in a highly reproducible manner in adult human β-cells regardless of sex, age, BMI, or isolation center.

Both LiCl and 1-Akp significantly enhanced DNA synthesis above that of 8 mmol/l glucose, and LiCl-mediated DNA synthesis was more sensitive to rapamycin than 1-Akp. This finding suggested that a component of 1-Akp--stimulated DNA synthesis in human islets is mTOR independent. Although lithium at higher concentrations decreased DNA synthesis in human islets, this did not appear to be due to apoptosis because cell cycle analysis ([Fig. 3*A* and *B*](#f3){ref-type="fig"}) failed to detect a significant degree of apoptosis under similar conditions. Mussmann et al. ([@r18]) reported that lithium produces toxic effects at concentrations \>3 mmol/l in the cell line, INS-1E, but this is not the case in human or rodent islets. Our studies also determined that the increase in DNA synthesis induced by lithium and 1-Akp in human islets was not due to the effects of endogenous insulin through the insulin signaling pathway ([Fig. 2*A*](#f2){ref-type="fig"}).

At basal glucose, lithium and 1-Akp produced a similar magnitude of entry of human and rat islet cells into the cell cycle. Human islet cells did not enter the cell cycle in response to 8 mmol/l glucose but required GSK-3 inhibition. In contrast, rat islets cells entered the cell cycle in response to 8 mmol/l glucose, which was further increased by both lithium and 1-Akp.

Although human islets treated for 4 days with 8 mmol/l glucose ± 1-Akp secreted insulin in response to 16.5 mmol/l glucose plus forskolin, a significant loss of insulin content in human islets occurred as a consequence of the 4-day culture in all treatment conditions. Efrat and colleagues ([@r26]) found that expanding dispersed human islets resulted in lower levels of insulin content, but subsequent treatment with β-cellulin resulted in redifferentiation with restoration of β-cell gene expression and insulin content. Although our treatment conditions enhance expansion of human β-cells, this strategy alone may not be optimal to maintain or restore differentiation. Our immunohistochemical analysis of the colocalization of Ki-67 or BrdU with insulin has provided insights into this objective. A number of human β-cells positive for Ki-67 or BrdU had only a few insulin granules in the cytoplasm ([Fig. 5*E*](#f5){ref-type="fig"}). Such poorly granulated cells were not included in our proliferation data, which may be an underestimation of actual human β-cell proliferation. This population of β-cells will be the focus of future studies aimed at maintaining or restoring insulin gene expression.

Studies also focused on gaining insights into the signaling mechanism whereby GSK-3 inhibition affects DNA synthesis, cell cycle progression, and proliferation in a rapamycin-sensitive manner. We observed that GSK-3 inhibition, in the presence of 5 or 8 mmol/l glucose, resulted in increases in β-catenin accumulation and translocation, whereas an increase in glucose concentration alone results only in β-catenin accumulation. The increase in β-catenin accumulation due to an increase in glucose concentration showed a small degree of rapamycin sensitivity. Importantly, β-catenin translocation in response to GSK-3 inhibition was significantly rapamycin sensitive and may represent an important mechanism responsible for the ability of rapamycin to inhibit DNA synthesis, cell cycle progression, and β-cell proliferation. Recent studies proposed that β-catenin signaling is both necessary and sufficient for β-cell proliferation in mouse islets ([@r27]) and that overexpression of GSK-3 in mice reduces β-cell mass ([@r28]). However, these studies did not address the role of mTOR in combination with β-catenin signaling as a requirement for rodent β-cell proliferation. In addition, Wnt3a treatment failed to stimulate human β-cell proliferation ([@r27]), suggesting that a more direct inhibition of GSK-3 may be required for β-catenin translocation. Mussmann et al. ([@r18]) demonstrated that GSK-3 inhibitors, 1-Akp and CHIR99021, promoted rat β-cell replication over the range of 1--20 μmol/l after 72-h incubation. These studies did not examine the effects of these inhibitors or the contribution of the nutrient glucose and the mTOR pathway in promoting human β-cell proliferation.

Recent studies by Inoki et al. ([@r29]) and Jin et al. ([@r30]) have identified in non--β-cells a key role for GSK-3, in a β-catenin--independent manner, to regulate mTOR signaling. They suggest that enhanced GSK-3 and AMP-activated protein kinase (AMPK) activities cooperate in the activation of TSC2 to inhibit mTOR activity. Collectively, their studies indicate that inhibition of GSK-3 is required for mTOR activation. Thus, we next examined whether GSK-3 inhibition has a positive effect on mTOR activation in human islets. GSK-3 inhibition exerted inconsistent and small effects on mTOR signaling in the presence of 5 or 8 mmol/l glucose ([Fig. 6*C* and *E*](#f6){ref-type="fig"}). In the absence of glucose, GSK-3 inhibitors resulted in a small increase in S6 phosphorylation (data not shown). As shown in [Fig. 8](#f8){ref-type="fig"}, both phosphorylation of GSK-3 and a decrease in AMPK due to increased nutrient metabolism play a key role in inhibiting TSC1/2 and in turn activate the mTOR pathway. Although our data demonstrate the existence of this pathway in primary islets, it is unclear at this point what role GSK-3 plays in mTOR regulation.

In contrast, mTOR exerts multiple effects on GSK-3 signaling in human β-cells ([Fig. 8](#f8){ref-type="fig"}). Chronic overactivation of mTOR/S6K1 leads to a negative feedback of the insulin signaling pathway and reduced Akt phosphorylation and indirectly activates GSK-3. Insulin dose responses ([Figs. 2](#f2){ref-type="fig"} and [6*F* and *G*](#f6){ref-type="fig"}) revealed that human islets failed to signal through the insulin signaling cascade. This suggests that under these in vitro conditions, human islets exhibit a relatively high level of insulin resistance. Furthermore, rapamycin restores insulin sensitivity, suggesting that even basal levels of mTOR activation sufficiently engage feedback inhibition of the insulin signaling cascade in human islets, resulting in insulin resistance. Zhang et al. ([@r31]) propose that mTOR-dependent feedback inhibition of Akt may also result in a feedforward mechanism to regulate GSK-3 in the absence of Akt input. Although our studies show that 8 mmol/l glucose increases β-catenin accumulation, suggesting that this feedforward mechanism may regulate GSK-3/β-catenin in human islets, it is unclear why this does not result in detectable β-catenin nuclear translocation.

Significant findings reported here are the synergistic effects of 8 mmol/l glucose and GSK-3 inhibition to enhance human β-cell proliferation. In addition, the rapamycin sensitivity of β-catenin nuclear translocation may explain, in part, the mechanism whereby rapamycin inhibits these regenerative processes. Our data suggest that although mTOR activity is necessary, even basal levels may result in engagement of negative feedback from S6K1 and result in a relatively high constitutive level of GSK-3 activity in human islets in vitro. This may explain the need for direct inhibition of GSK-3 with therapeutic agents. Overall, these studies suggest that appropriate regulation of mTOR and GSK-3/β-catenin signaling in combination with strategies to maintain or restore differentiation may provide available approaches to expand human β-cell mass.
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![Dose response of LiCl and 1-Akp on mTOR-dependent DNA synthesis in human and rat islets. Human (*A* and *B*) or rat (*C* and *D*) islets (100) were cultured for 4 days in CMRL-1066 medium containing 10% FBS, 8 mmol/l glucose ± rapamycin, LiCl, or 1-Akp as indicated. \[^3^H\]thymidine was added to each dish 24 h before the end of the 4-day period. Data are the means ± SE; *n* = 3 experiments (except at 15 mmol/l LiCl *n* = 2) (*A*); *n* = 5 experiments (except at 15 μmol/l 1-Akp *n* = 2) with duplicate or triplicate samples in each experiment (*B*); *n* = 3 with duplicate samples in each experiment (*C* and *D*). \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 indicate significant differences from 8 mmol/l glucose alone. ▪, 8 mmol/l glucose; □, 8 mmol/l glucose + Rap 25 nmol/l; •, 8 mmol/l glucose + Rap 100 nmol/l.](zdb0030956560001){#f1}

![Effects of exogenous insulin on mTOR-dependent DNA synthesis in human and rat islets. Human islets (*A*) or rat islets (*B*) (100) were cultured for 4 days in CMRL-1066 medium containing 10% FBS, 5 mmol/l glucose ± rapamycin, insulin, or 1-Akp as indicated. \[^3^H\]thymidine was added to each dish 24 h before the end of the 4-day period. Data are the means ± SE of *n* = 3 experiments with triplicate samples in each experiment. \*\**P* \< 0.01 and \*\*\**P* \< 0.001 denote significant differences between the bracketed conditions. cpm, counts per minute.](zdb0030956560002){#f2}

![Lithium- and 1-Akp--mediated promotion of cell cycle progression in human and rat islet cells is blocked by rapamycin. Human (*A*--*C*) and rat (*D* and *E*) (200) islets were cultured in CMRL containing 10% FBS, 5 or 8 mmol/l glucose, and LiCl or 1-Akp ± rapamycin as indicated. At the end of the 4-day incubation period, islets were dispersed into single cells and processed as described in [research design and methods]{.smallcaps} to determine cell cycle progression. Data are the means ± SE of *n* = 2 experiments with duplicate samples in each experiment (*A* and *B*; *A*: □, 5 mmol/l glucose; ▪, 5 mmol/l glucose + 10 mmol/l LiCl; ![](cjs2113.jpg), 5 mmol/l glucose + 10 mmol/l LiCl + 100 nmol/l rapamycin. *B*: □, 5 mmol/l glucose; ▪, 5 mmol/l glucose + 15 μmol/l 1-Akp; ![](cjs2113.jpg), 5 mmol/l glucose + 15 μmol/l 1-Akp + 100 nmol/l rapamycin.), *n* = 3 experiments with duplicate samples (*C*; □, 5 mmol/l glucose; ![](cjs2106.jpg), 8 mmol/l glucose; ![](cjs2112.jpg), 8 mmol/l glucose + 100 nmol/l rapamycin; ▪, 8 mmol/l glucose + 15 μmol/l 1-Akp; ![](cjs2113.jpg), 8 mmol/l glucose + 15 μmol/l 1-Akp + 100 nmol/l rapamycin), *n* = 2 experiments with duplicate samples (*D*; □, 5 mmol/l glucose; ▪, 5 mmol/l glucose + 10 mmol/l LiCl; ![](cjs2112.jpg), 8mmol/l glucose; ![](cjs2113.jpg), 8 mmol/l glucose + 10 mmol/l LiCl), and *n* = 3 experiments with triplicate samples (*E*; □, 5 mmol/l glucose; ▪, 8 mmol/l glucose; ![](cjs2112.jpg), 8 mmol/l glucose + 15 μmol/l 1-Akp; ![](cjs2113.jpg), 8 mmol/l glucose + 15 μmol/l 1-Akp + 100 nmol/l rapamycin). \*\**P* \< 0.01 and \*\*\**P* \< 0.001 denote significant differences between the bracketed conditions.](zdb0030956560003){#f3}

![Glucose-stimulated insulin secretion and insulin content in human and rat islets. Human (*A* and *B*) or rat (*C* and *D*) islets were cultured in CMRL-1066 medium containing 10% FBS, 8 mmol/l glucose ± LiCl or 1-Akp as indicated. At the end of 4 days, islets were incubated for 1 h in CMRL containing 5 mmol/l glucose and then four to eight aliquots of 10 islets were counted for each treatment group. Islets were preincubated for 30 min in CMRL (5 mmol/l glucose), and medium was replaced with CMRL 5, 16.5 mmol/l glucose, or 16.5 mmol/l glucose + 10 μmol/l forskolin for 30 min. Supernatants and islet insulin content were assayed by radioimmunoassay. Insulin content from three to four aliquots of 10 islets was also measured at the start of the incubation period (Time 0). Data are the means ± SE from *n* = 3 experiments with duplicate or quadruplicate samples in each experiment. *A* and *C*: \*\**P* \< 0.01 and \*\*\**P* \< 0.001 indicate significant differences from 5 mmol/l glucose alone or with LiCl or 1-Akp. *B*: \*\*\**P* \< 0.001 indicates significant differences between Time 0 and 4-day incubation with 8 mmol/l glucose alone or with LiCl or 1-Akp.](zdb0030956560004){#f4}

![Lithium and 1-Akp in combination with glucose stimulates β-cell proliferation in human islets. *A*: Representative confocal image of paraffin-embedded intact human islets treated for 4 days with 8 mmol/l glucose and 5 mmol/l lithium. Image on the *left* was captured at 40×/1.3 oil objective showing nuclear Ki-67 expression (red) in insulin^+^ β-cells (green). On the *right* (from *inset* on *top left*) is a Z-Stack image taken at fivefold magnification to display confirmed colocalization of Ki-67 (red nuclei) and insulin (green cytoplasm) in two adjacent β-cells or a dividing β-cell. *C*: Representative immunofluorescent image of β-cell proliferation in dispersed islet cells treated for 4 days with 8 mmol/l glucose with 5 μmol/l 1-Akp as measured by BrdU incorporation (red nucleus) in insulin^+^ β-cells (green cytoplasm). Nuclei were stained with DAPI (blue). BrdU^+^ β-cell in the merged image is seen as a pink nucleus surrounded by green cytoplasm. *B* and *D*: Fold increase (with respect to 5 mmol/l glucose) in the ratio of proliferating β-cells to total number of insulin^+^ β-cells. Data presented are the mean ± SE of three independent experiments, with duplicate samples. For each group, ∼18,000 β-cells counted. *E*: Representative image of a poorly granulated β-cell showing BrdU incorporation (pink nucleus). On the *right* is a magnified image of the *inset*. *B* and *D*: \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 indicate significant differences between the bracketed conditions. (Please see <http://dx.doi.org/10.2337/db07-1208> for a high-quality digital representation of this figure.)](zdb0030956560005){#f5}

![GSK-3 and mTOR signaling in human islets. *A*--*G*: Human islets (100) were treated for 30 min in CMRL-1066 medium containing 0.1% BSA, 5 or 8 mmol/l glucose ± rapamycin, insulin (*F* and *G*), LiCl (*A*--*C*), or 1-Akp (*D* and *E*). Samples were processed for Western blotting and quantitated by densitometry. β-Actin was used as a protein loading control. Data are the means ± SE of *n* = 3 experiments, except *n* = 2 in *F*. \*\**P* \< 0.01 indicates significant difference between the bracketed conditions.](zdb0030956560006){#f6}

![Translocation of β-catenin in human islets. *A*: Fold increase in β-catenin nuclear translocation/insulin^+^ cells with respect to 5 mmol/l glucose. Data presented are the means ± SE of three independent experiments. For each group per experiment, ∼5,000--6,000 β-cells were counted. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 denote significant differences between the bracketed conditions. *B*: Representative immunofluorescent images of human islets treated for 1 day with 5 mmol/l glucose and 5 mmol/l LiCl ± 25 nmol/l rapamycin then dispersed into single cells and stained. Red, cytoplasmic β-catenin; purple center with red ring, translocated nuclear β-catenin; green, insulin^+^ β-cells. Nuclei were stained with DAPI (blue). *C*: Examples of cellular immunostaining used for quantitation criteria of nuclear β-catenin staining in β-cells. a: insulin positive (green cytoplasm), nuclear β-catenin positive (purple nucleus). b: insulin positive (green cytoplasm), nuclear β-catenin negative (blue nucleus). c: insulin negative, nuclear β-catenin positive (purple nucleus; red nuclear ring). d: insulin negative, nuclear β-catenin negative (blue nucleus). (Please see <http://dx.doi.org/10.2337/db07-1208> for a high-quality digital representation of this figure.)](zdb0030956560007){#f7}

![Proposed model involving GSK-3 inhibition and the mTOR pathway to stimulate human β-cell growth and proliferation. Increased nutrient metabolism inhibits AMPK activity, and LiCl or 1-Akp directly inhibits GSK-3. This blocks TSC1/2, resulting in mTOR activation and signaling to 4EBP1 and S6K1. An increased glucose concentration and/or GSK-3 inhibition results in increases in β-catenin steady-state levels. Direct inhibition of GSK-3 with LiCl or 1-Akp mediates β-catenin nuclear translocation that is rapamycin sensitive. Overactivation of mTOR/S6K1 results in feedback inhibition of IRS1/2 and Akt signaling. Overactivation of mTOR/S6K1 may also provide a feedforward mechanism that inhibits GSK-3 and increases in β-catenin steady-state levels but does not result in nuclear translocation (dashed line indicates a proposed pathway). AMPK, AMP-activated protein kinase; Rheb, Ras homolog enriched in brain; TSC, tuberous sclerosis complexes 1 and 2.](zdb0030956560008){#f8}
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